Hepatitis B doubly spliced protein (HBDSP) promotes hepatocellular carcinoma cell apoptosis via ETS1/GATA2/YY1-mediated p53 transcription

J Virol. 2023 Nov 30;97(11):e0108723. doi: 10.1128/jvi.01087-23. Epub 2023 Nov 6.

Abstract

Hepatitis B virus (HBV) spliced variants are associated with viral persistence or pathogenicity. Hepatitis B doubly spliced protein (HBDSP), which has been previously reported as a pleiotropic transactivator protein, can potentially serve as an HBV virulence factor. However, the underlying mechanisms of HBDSP in HBV-associated liver diseases remain to be elucidated. In this study, we revealed that HBDSP promotes cellular apoptosis and induces wt-p53-dependent apoptotic signaling pathway in wt-p53 hepatocellular cells by transactivating p53 transcription, and increases the release of HBV progeny. Therefore, HBDSP may promote the HBV particles release through wt-p53-dependent hepatocellular apoptosis. Our findings suggest that blocking HBDSP-induced wt-p53-dependent apoptosis might have therapeutic values for chronic hepatitis B.

Keywords: RNA splicing; apoptosis; hepatitis B virus; p53; transactivator protein.

MeSH terms

  • Apoptosis*
  • Carcinoma, Hepatocellular* / virology
  • GATA2 Transcription Factor / metabolism
  • Hepatitis B virus / genetics
  • Hepatitis B virus / metabolism
  • Hepatitis B* / complications
  • Humans
  • Liver Neoplasms* / virology
  • Proto-Oncogene Protein c-ets-1 / metabolism
  • Tumor Suppressor Protein p53 / genetics
  • Tumor Suppressor Protein p53 / metabolism
  • YY1 Transcription Factor / metabolism

Substances

  • ETS1 protein, human
  • GATA2 protein, human
  • GATA2 Transcription Factor
  • Proto-Oncogene Protein c-ets-1
  • Tumor Suppressor Protein p53
  • YY1 protein, human
  • YY1 Transcription Factor